Stockreport

Loxo Oncology Announces Receipt of Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-292 for the Treatment of RET Fusion-Positive Thyroid Cancer

LOXO ONCOLOGY  (LOXO) 
Last loxo oncology earnings: 11/8 06:45 am Check Earnings Report
US:NASDAQ Investor Relations: ir.loxooncology.com
PDF STAMFORD, Conn., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients wi [Read more]